Physician profile
Spencer Hatch
NPI 1518321496
$2,243.14
in general payments reported to CMS, 2019-2025
18 companies · $621 in 2025
The $621 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $114 · 2021: $365 · 2022: $290 · 2023: $342 · 2024: $510 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,473.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $863.42 | 2021-2025 | Lokelma, Farxiga |
| Mallinckrodt Hospital Products INC. | $230.40 | 2020-2025 | Acthar, Terlivaz |
| Alexion Pharmaceuticals, INC. | $181.51 | 2022-2025 | Ultomiris |
| Calliditas Therapeutics US INC. | $153.84 | 2023-2025 | Tarpeyo |
| Akebia Therapeutics INC | $121.55 | 2021-2024 | Vafseo |
| Ani Pharmaceuticals, INC. | $98.51 | 2024-2025 | Purified Cortrophin Gel |
| Amgen INC. | $98.48 | 2022-2024 | Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $78.07 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $72.23 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $64.16 | 2022-2025 | Velphoro |
| Vifor Pharma, INC. | $58.02 | 2023-2025 | Veltassa, Korsuva |
| Glaxosmithkline, LLC. | $53.83 | 2023-2025 | Shingrix, Arexvy, Jesduvroq |
| Scpharmaceuticals INC. | $39.11 | 2025 | |
| Apellis Pharmaceuticals, INC. | $38.59 | 2025 | Empaveli |
| Otsuka America Pharmaceutical, INC. | $29.51 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $26.59 | 2023 | Injectafer |
| Biogen, INC. | $21.73 | 2021 | |
| Boston Scientific Corporation | $13.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Hatch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.